Clinical Trial Update: Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating the safety and efficacy of a 30 mcg sufentanil sublingual tablet for moderate-to-severe acute pain; results have been posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pain

Drugs mentioned

• Sufentanil Sublingual Tablet 30 mcg (sufentanil)

Snippet

Sponsor: Talphera, Inc | Conditions: Moderate-to-severe Acute Pain | Phase 3 | Status: COMPLETED | Results posted: 2017-10-19